
Sunshine Biopharma Inc.: updates and filings
Price
$2.54
November 17, 2026Market cap $2.1M
What Ploutos Investor adds for Sunshine Biopharma
Part of Ploutos Investor, €9.99 a month
- The full history: 16 fiscal years, from 2010
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
An estimate from when it has reported before, and the timing has varied a little. The company announces the date itself.
October 2026
August 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 13, 2026Additional annual meeting materialFormDEFA14A
- Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 12, 2026Annual meeting proxy statementFormDEF 14A
- Nov 10, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 27, 2026DEFINITIVE INFORMATION STATEMENTFormDEF 14C
- Oct 14, 2026PRELIMINARY INFORMATION STATEMENTFormPRE 14C
- Oct 14, 2026Shareholder voteForm8-K
- Oct 14, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Oct 13, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Oct 9, 2026Material agreement entered, other material eventsForm8-K
- Oct 7, 2026FilingFormEFFECT
- Oct 5, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 2, 2026FORM S-1FormS-1
- Sep 28, 2026DEFINITIVE INFORMATION STATEMENTFormDEF 14C
- Sep 24, 2026FilingFormDRS
- Sep 16, 2026PRELIMINARY PROXYFormPRE 14C
- Sep 16, 2026Shareholder voteForm8-K
- Sep 11, 2026Other material eventsForm8-K
- Sep 8, 2026FilingFormEFFECT
- Aug 28, 2026FORM S-1FormS-1
- Aug 28, 2026Officer or director changeForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 13, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 3, 2026Other material eventsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 13, 2026 | DEFA14A | Additional annual meeting material | Document |
| Nov 12, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 12, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Nov 10, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 27, 2026 | DEF 14C | DEFINITIVE INFORMATION STATEMENT | Document |
| Oct 14, 2026 | PRE 14C | PRELIMINARY INFORMATION STATEMENT | Document |
| Oct 14, 2026 | 8-K | Shareholder vote | Document |
| Oct 14, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Oct 13, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Oct 9, 2026 | 8-K | Material agreement entered, other material events | Document |
| Oct 7, 2026 | EFFECT | Filing | Document |
| Oct 5, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 2, 2026 | S-1 | FORM S-1 | Document |
| Sep 28, 2026 | DEF 14C | DEFINITIVE INFORMATION STATEMENT | Document |
| Sep 24, 2026 | DRS | Filing | Document |
| Sep 16, 2026 | PRE 14C | PRELIMINARY PROXY | Document |
| Sep 16, 2026 | 8-K | Shareholder vote | Document |
| Sep 11, 2026 | 8-K | Other material events | Document |
| Sep 8, 2026 | EFFECT | Filing | Document |
| Aug 28, 2026 | S-1 | FORM S-1 | Document |
| Aug 28, 2026 | 8-K | Officer or director change | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 13, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 3, 2026 | 8-K | Other material events | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since May 25, 2007.
The full analysis
What do Sunshine Biopharma's filings show?
The filings are where every one of Sunshine Biopharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.